News
Feb 2010
Crossover is pleased to announce that the new offices of its Clinical Research Unit in Sofia, Bulgaria, are now conveniently located in very short distance on foot from Doverie Hospital.
Aug 2009

Crossover CRI opens a Clinical Research Unit at Doverie Hospital in Sofia, Bulgaria


    ZUG, Switzerland, August 12, 2009. -- Crossover CRI AG ("Crossover"), a leading provider of clinical research support staff and services to healthcare institutions, announced that it executed a master clinical research partnership agreement with Doverie Hospital in Sofia, Bulgaria on 11 August, 2009.

Dr. Peter Keremedchiev, Executive Director of Doverie Hospital said: “Our hospital offers state-of-the-art medical care. Participating in clinical trials of international importance is a key mission of our doctors and nursing staff. Patients come to Doverie Hospital also because they know they can find access to drugs and devices which are not accessible yet outside clinical trials. Our collaboration with Crossover will boost the image of our hospital with pharmaceutical and biotechnology companies internationally.”

According to Dr. Jean-Pierre Tassignon, President & CEO of Crossover, “The Crossover Clinical Research Unit (CRU) at Doverie Hospital is the first investment of Crossover in Eastern Europe, which plays an increasingly important role in clinical research. Crossover is confident that clinical research at Doverie Hospital will develop rapidly because the global clinical research market needs elite hospitals with the equipment and talent to conduct modern clinical trials.” He sees synergistic effects with the large CRU Crossover has already set up at CHU Brugmann hospital and the HUDERF pediatric hospital in Brussels, Belgium.

The quality requirements in clinical research continue to increase. The complexity of clinical trial protocols is doubling every five years according to a study by Tufts University in the United States. Clinical trials now involve a lot of genomic and proteomic research parameters and electronic data transfer. The Crossover office in Bulgaria headed by Dr Velizar Tchernev will provide key support to the new CRU.
Crossover confirmed that it is in negotiation with other specialist hospitals in the European Union in order to continuously expand its clinical research infrastructures network.

About Doverie Hospital
The Doverie Medical Complex in Sofia, Bulgaria is located on an area of 8,000 sqm. Medical activities cover general surgery, internal medicine, urology, orthopedics, plastic surgery, gynecology, anesthesiology, gastroenterology, cardiology, nephrology, neurology and physical and rehabilitation medicine. The Hospital has a laboratory, a pharmacy, and imaging facilities. It has its own ethics committee.

About Crossover CRI AG.
Crossover CRI AG (Crossover) is currently establishing a large international network of Clinical Research Units (CRUs) at research-driven healthcare institutions. Its CRUs are located on-site at the healthcare institution to enable the collection and analysis of healthcare information both in clinical trials and epidemiology studies.

Crossover invests in establishing and staffing the CRUs that are responsible for conducting all clinical trials carried out at the selected healthcare institutions which are part of the Crossover network. The Crossover network of CRUs conducts clinical trials according to the same standards throughout the network.

Further information can be found as follows:
Contact: Dr Velizar Tchernev, International Director of Clinical Research Technology and Regional Director South-East Europe, Sofia, Bulgaria
Mobile: +359 885 59 7109
E-mail: Velizar.Tchernev@crossover-cri.com.
SOURCE Crossover CRI (=Clinical Research Infrastructures) Group.
http://www.crossover-cri.com

 

Mar 2009

Fraud and misconduct in clinical trials – How pervasive in the world? 

In a recent article published in the January 2009 issue of the Journal for Clinical Studies, Crossover’s President points to the alarming increase in fraud and misconduct, as well as questionable research practices worldwide in the domain of clinical research. He speculates that some of the extraordinary moneys invested in external monitoring by sponsors should be better invested in strengthening research oversight inside healthcare institutions hosting investigators. Link

Jan 2009
A team including Velizar Tchernev, International Director Technology Division and Director South East Europe at Crossover, recently published a peer-reviewed article in Molecular & Cellular Proteomics about the identification of diagnostic biomarkers for infection in premature neonates. Using immunoassays multiplexed on microarrays, more than 100 cytokines were measured in small volumes of serum to identify differentially expressed proteins in clinically infected and non-infected neonates. Significant alterations were revealed in the levels of 8 serum proteins associated with inflammation, coagulation, and fibrinolysis. Multivariate classifiers based on combinations of serum analytes exhibited better diagnostic specificity and sensitivity than single analytes. Multiplexed immunoassays of serum cytokines may have clinical utility as an adjunct for rapid diagnosis of infection and differentiation of etiologic agents in neonates with clinical decompensation. Link
Dec 2008

HUDERF and its Crossover Clinical Research Unit join the Belgian Pediatric Clinical Research Network

The BPCRN held its first meeting on 17 December, 2008 under the chairmanship of Dr Daniel Brasseur, chairman of the new Paediatric Committee of the EMEA, and under the auspices of the Belgian Professional Association of Pediatricians as well as the Belgian Federal Agency for Medicines and Health Products. The BPCRN is the response of Belgium as a Member State of the European Union to the European Paediatric Research Network which is being instituted by EU Regulation 1901/2006 of 12 December, 2006: the EMEA is charged with creating a European-wide pediatric network capable of accommodating the numerous clinical trials which are planned as part of a growing number of PIPs being approved. A PIP is a Pediatric Investigation Plan agreed between the manufacturer of a medicinal product with a pediatric indication and EMEA. The Hôpital Universitaire des Enfants Reine Fabiola (HUDERF) is one of the largest pediatric hospitals in Europe with 160+ beds and a new wing under construction.

archive
  • Crossover is pleased to
    announce that the new
    offices of its Clinical
    Research Unit in Sofia, ... more
  • Crossover CRI opens a
    Clinical Research Unit at
    Doverie Hospital in Sofia,
    Bulgaria    ... more
  • Fraud and misconduct in
    clinical trials – How
    pervasive in the
    world?  In a recent ... more
  • BEAPP 4th Annual Scientific
    Conference on 18 March
    2010, Diamant Center,
    Brussels    ... more
  • EFGCP Annual Conference on
    26-27 January 2010 in
    Brussels  Jean-Pierre
    Tassignon will open the ... more
  • EFGCP Multidisciplinary
    Workshop on 7 July 2009,
    Diamant Center,
    Brussels   This ... more